AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

10x Genomics Inc. (TXG)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

11.57

-0.53 (-4.38%)

At close: Feb 20, 2025, 3:59 PM

11.79

1.82%

After-hours: Feb 20, 2025, 05:07 PM EST

undefined% (undefined)

Bid	11.56
Market Cap	1.42B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.52
PE Ratio (ttm)	-7.62
Forward PE	n/a
Analyst	Hold

Ask	11.99
Volume	1,855,182
Avg. Volume (20D)	2,225,855
Open	12.10
Previous Close	12.10
Day's Range	11.49 - 12.16
52-Week Range	10.80 - 48.42
Beta	undefined

About TXG

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene...

[Show more]

Industry Medical - Healthcare Information Services

Sector Healthcare

IPO Date Sep 12, 2019

Employees 1,306

Stock Exchange NASDAQ

Ticker Symbol TXG

Website https://www.10xgenomics.com

Full Company Profile

Analyst Forecast

According to 16 analyst ratings, the average rating for TXG stock is "Hold." The 12-month stock price forecast is $19, which is an increase of 64.15% from the latest price.

Buy 43.75%

Hold 50.00%

Sell 6.25%

Stock Forecasts

Next Earnings Release

10x Genomics Inc. is scheduled to release its earnings on Apr 29, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-0.5%

10x Genomics shares are trading lower after Leerin... Unlock content with Pro Subscription

1 week ago

-15.37%

10x Genomics shares are trading lower after Barclays maintained an Overweight rating on the stock and lowered its price target from $19 to $18.

News

2 days ago · newsfilecorp.com

Torex Gold Reports Q4 and Full Year 2024 Results

2024 marks another solid year of operational and financial results; on track to return to positive free cash flow generation by mid-2025 (All amounts expressed in U.S. dollars unless otherwise stated)...

1 week ago · benzinga.com

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties

On Wednesday, 10x Genomics Inc TXG reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of $(0.30).

1 week ago · seekingalpha.com

10x Genomics, Inc. (TXG) Q4 2024 Earnings Call Transcript

10x Genomics, Inc. (NASDAQ:TXG ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Cassie Corneau - Senior Director, IR and Strategic Finance Serge Saxonov - CEO and C...

1 week ago · zacks.com

Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street e...

1 week ago · zacks.com

10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates

10x Genomics (TXG) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.41 per share a year ago.

1 week ago · zacks.com

Seeking Clues to 10x Genomics (TXG) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during th...

2 weeks ago · finbold.com

Cathie Wood dumped Palantir to buy these biotech stocks

Ark Invest Management chief executive officer (CEO) Cathie Wood is a lauded yet controversial figure.

2 weeks ago · zacks.com

10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · newsfilecorp.com

Torex Gold Provides Q4 2024 Update on Media Luna Project

Construction substantially complete and first copper concentrate on track for March (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - February 4, 2025...

2 weeks ago · 247wallst.com

Cathie Wood's Top Biotech Plays for February

Don't look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns.

Load More News